NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Cover of Atypical Antipsychotics for Schizophrenia: Combination Therapy and High Doses

Atypical Antipsychotics for Schizophrenia: Combination Therapy and High Doses

CADTH Optimal Use Report, No. 1.1


Optimizing drug-related health outcomes and the cost-effective use of drugs is a goal of the Canadian Agency for Drugs and Technologies in Health (CADTH). Where possible, CADTH builds on existing applicable Canadian and international initiatives and research.

CADTH goals are achieved through three main approaches:

  • Identifying evidence-based optimal use in the prescribing and use of specific drugs
  • Identifying gaps between clinical practice, then proposing evidence-based interventions to address these gaps
  • Supporting the implementation of these interventions.

Direction and advice are provided to CADTH through various channels, including the following:

  • The former Canadian Optimal Medication Prescribing and Utilization Service (COMPUS) Advisory Committee (CAC) and the former Advisory Committee on Pharmaceuticals (ACP), which include representatives from the federal, provincial, and territorial health ministries and related health organizations
  • The Drug Policy Advisory Committee (DPAC)
  • The DPAC Optimal Use Working Group (OUWG)
    • DPAC and its OUWG were formed following the selection of this report’s topic
  • The COMPUS Expert Review Committee (CERC)
  • Stakeholder feedback.


This report is prepared by the Canadian Agency for Drugs and Technologies in Health (CADTH). This report contains a review of existing public literature, studies, materials, and other information and documentation (collectively the “source documentation”) available to CADTH at the time it was prepared, and it was guided by expert input and advice throughout its preparation.

The information in this report is intended to help health care decision-makers, patients, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. The information in this report should not be used as a substitute for the application of clinical judgment in respect to the care of a particular patient or other professional judgment in any decision-making process, nor is it intended to replace professional medical advice. While CADTH has taken care in the preparation of this report to ensure that its contents are accurate, complete, and up-to-date, CADTH does not make any guarantee to that effect. CADTH is not responsible for any errors or omissions or injury, loss, or damage arising from or as a result of the use (or misuse) of any information contained in or implied by the information in this report.

CADTH takes sole responsibility for the final form and content of this report. The statements, conclusions, and views expressed herein do not necessarily represent the view of Health Canada or any provincial or territorial government.

Production of this report is made possible through a financial contribution from Health Canada.

Copyright © 2011 Canadian Agency for Drugs and Technologies in Health.
Bookshelf ID: NBK169697PMID: 24278996
PubReader format: click here to try


Other titles in this collection

Related information

Related citations in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...